The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Klintman, Marie ^a,b   Strand, Carina ^a   Ahlin, Cecilia ^c   Beglerbegovic, Sanda ^d   Fjällskog, Marie Louise ^e   Grabau, Dorthe ^a   Gudlaugsson, Einar ^f   Janssen, Emiel A M ^f   Lövgren, Kristina ^a   Skaland, Ivar ^f   Bendahl, Pär Ola ^a   Malmström, Per ^a,b   Baak, Jan P A ^f   Fernö, Mårten ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HISTONE H3; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MITOTIC ACTIVITY INDEX; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; PREMENOPAUSE; PROTEIN ANALYSIS; REFERENCE VALUE; TISSUE MICROARRAY;

BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN A; CYCLIN B1; DISEASE-FREE SURVIVAL; FEMALE; HISTONES; HUMANS; KI-67 ANTIGEN; LYMPH NODES; MITOTIC INDEX; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 84891893232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081902     Document Type: Article

References (46)

1. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65. doi:10.1186/bcr1949. PubMed: 18662380.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752. doi:10.1038/35021093. PubMed: 10963602.
3. Paik S, Shak S, Tang G, Kim C, Baker J et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826. doi:10.1056/NEJMoa041588. PubMed: 15591335.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. doi:10.1073/pnas.191367098. PubMed: 11553815.
5. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. doi:10.1038/415530a. PubMed: 11823860.
6. Ivshina AV, George J, Senko O, Mow B, Putti TC et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301. doi:10.1158/0008-5472.CAN-05-4414. PubMed: 17079448.
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272. doi:10.1093/jnci/djj052. PubMed: 16478745.
8. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312. doi:10.1200/JCO. 2007.14.2364. PubMed: 17954709.
9. Prat A, Parker JS, Fan C, Cheang MC, Miller LD et al. (2012) Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 23: 2866-2873. doi:10.1093/annonc/mds080. PubMed: 22532584.
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B et al. (2011) Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747. doi:10.1093/annonc/mdr304. PubMed: 21709140.
11. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664. doi:10.1093/jnci/djr393. PubMed: 21960707.
12. Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z et al. (2012) Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology 61: 1134-1144. doi:10.1111/j.1365-2559.2012.04329.x. PubMed: 22963617.
13. Skaland I, van Diest PJ, Janssen EA, Gudlaugsson E, Baak JP (2008) Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum Pathol 39: 584-590. doi:10.1016/j.humpath. 2007.08.016. PubMed: 18291440.
14. Baak JP, van Diest PJ, Janssen EA, Gudlaugsson E, Voorhorst FJ et al. (2008) Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Ann Oncol 19: 649-654. PubMed: 18042836.
15. Lende TH, Janssen EA, Gudlaugsson E, Voorhorst F, Smaaland R et al. (2011) In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol 29: 852-858. doi: 10.1200/JCO.2009.25.0407. PubMed: 21189388.
16. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV et al. (2007) The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 43: 527-535. doi:10.1016/j.ejca. 2006.10.001. PubMed: 17110097.
17. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S et al. (1993) Predictive value of a morphometric prognostic index in female breast cancer. Oncology 50: 57-62. doi:10.1159/000227148. PubMed: 8421599.
18. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F et al. (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914-1921. doi:10.1002/1097-0142(19891101)64:9. PubMed: 2551477.
19. Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7: 1716-1723. PubMed: 11410511.
20. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV et al. (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23: 5993-6001. doi: 10.1200/JCO.2005.05.511. PubMed: 16135467.
21. Gudlaugsson E, Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ et al. (2010) Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer. Breast Cancer Res Treat 121: 35-40. doi:10.1007/s10549-009-0442-x. PubMed: 19568929.
22. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E et al. (2000) Histologic grading in breast cancer - reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 39: 41-45. doi:10.1080/028418600430950. PubMed: 10752652.
23. Harvey JM, de Klerk NH, Sterrett GF (1992) Histological grading in breast cancer: interobserver agreement, and relation to other prognostic factors including ploidy. Pathology 24: 63-68. doi:10.3109/00313029209063625. PubMed: 1641262.
24. van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM et al. (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23: 603-607. doi:10.1016/0046-8177(92)90313-R. PubMed: 1592381.
25. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T et al. (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106: 348-360. doi:10.1007/s004120050256. PubMed: 9362543.
26. Juan G, Traganos F, James WM, Ray JM, Roberge M et al. (1998) Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 32: 71-77. doi:10.1002/(SICI)1097-0320(19980601)32:2. PubMed: 9627219.
27. Skaland I, Janssen EA, Gudlaugsson E, Hui Ru Guo L, Baak JP (2009) The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell Oncol 31: 261-271.
28. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH et al. (2007) Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol 20: 1307-1315. doi:10.1038/modpathol.3800972. PubMed: 17917671.
29. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH et al. (2009) Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat 114: 39-45. doi:10.1007/s10549-008-9980-x. PubMed: 18373192.
30. Nimeus-Malmstrom E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L et al. (2009) Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer.
31. Rudolph P, Kühling H, Alm P, Fernö M, Baldetorp B et al. (2003) Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 105: 674-680. doi:10.1002/ijc.11132. PubMed: 12740917.
32. Suzuki T, Urano T, Miki Y, Moriya T, Akahira J et al. (2007) Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 98: 644-651. doi:10.1111/j.1349-7006.2007.00444.x. PubMed: 17359284.
33. Koliadi A, Nilsson C, Holmqvist M, Holmberg L, La Torre MD et al. (2010) Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer. Acta Oncol, 49: 816-20. PubMed: 20307242.
34. Strand C, Ahlin C, Bendahl PO, Fjällskog ML, Hedenfalk I et al. (2012) Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat 131: 33-40. doi:10.1007/s10549-011-1386- 5. PubMed: 21331623.
35. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML et al. (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51: 491-498. doi:10.1111/j.1365-2559. 2007.02798.x. PubMed: 17711446.
36. Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C et al. (2009) Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18: 2501-2506. doi:10.1158/1055-9965. EPI-09-0169. PubMed: 19706846.
37. Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I et al. (2001) S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 19: 2010-2019. PubMed: 11283134.
38. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M et al. (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100: 229-235. doi:10.1007/s10549-006-9242-8. PubMed: 16932852.
39. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410. doi:10.1111/j.1365-2559.1991.tb00229.x. PubMed: 1757079.
40. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P et al. (2010) The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 23: 251-259. doi:10.1038/modpathol.2009.167. PubMed: 19935641.
41. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM et al. (1989) The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185: 664-670. doi:10.1016/S0344-0338(89)80213-4. PubMed: 2696948.
42. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69: 239-241. doi:10.1093/biomet/69.1.239.
43. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398. doi:10.1073/pnas.1732912100. PubMed: 12917485.
44. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8: R157. doi:10.1186/gb-2007-8-8-r157. PubMed: 17683518.
45. Gudlaugsson E, Klos J, Skaland I, Janssen EA, Smaaland R, et al. (2013) Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T(1)(-)(2)N(0)M(0) breast cancer. Pol J Pathol 64: 1-8.
46. Skaland I, Nordhus M, Gudlaugsson E, Klos J, Kjellevold KH et al. (2010) Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol 18: 90-96. doi:10.1097/PAI.0b013e3181b0eaad. PubMed: 19661787.